Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system

Journal of Nuclear Medicine

Volumn 39, Issue 10, 1998, Pages 1813-1818

  Goodwin, David A ^a   Meares, Claude F ^a   Osen, Maureen ^a  

^a Vet Aff Palo Alto Hlth Care Syst ^*

Author keywords

Indium 111; Pretargeting; Radioimmunoimaging; Radioimmunotherapy; Yttrium90

Indexed keywords

AVIDIN; BIOTIN; EDETIC ACID; INDIUM 111; MONOCLONAL ANTIBODY; STREPTAVIDIN; YTTRIUM 90;

ANIMAL TISSUE; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC IMAGING; IMMUNOSCINTIGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION; TUMOR LOCALIZATION;

ANIMALS; BIOTIN; CHELATING AGENTS; INDIUM RADIOISOTOPES; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, SCID; RADIOIMMUNODETECTION; RADIOIMMUNOTHERAPY; STREPTAVIDIN; TISSUE DISTRIBUTION; YTTRIUM RADIOISOTOPES;

EID: 0031687309     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Yuanfang L, Chuanchu W. Radiolabeling of monoclonal antibodies with metal chelates. Pure Appl Chem 1991;3:427-463.
2. Meares CF, Moi MK, Diril H, et al. Macrocyclic chelates of radiometals for diagnosis and therapy. Br J Cancer 1990;62:21-26.
3. Bloomer WD, Lipsztein R, Dalton JF. Antibody mediated radiotherapy. Cancer 1985;55:2229-2233.
4. DeNardo SJ, DeNardo GL, Peng J-S, Colcher D. Monoclonal antibody radiopharmaceuticals for cancer radioimmunotherapy. In: Burchiel S, Rhodes B, eds. Radioimmunoimaging and radioimmunotherapy. New York: Elsevier; 1983:409-417.
5. 131I-Lym-A. Cancer Res 1990;50: 10145-10165.
6. Halpern SE, Hagen PL, Garver PR, et al. Stability, characterization and kinetics of indium-111-labeled monoclonal antitumor antibodies in normal animals and nude mouse-human tumor models. Cancer Res 1983;43:5347-5355.
7. Hnatowich DJ, Layne RL, Lanteigne D, Davis MA. Radioactive labelling of antibody: a simple and efficient method. Science 1982;220:613-615.
8. Deshpande SV, DeNardo SJ, Kukis DL, et al. Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent. J Nucl Med 1990;31:473-479.
9. Kozak RW, Raubitschek A, Mirzadeh S, et al. Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity. Cancer Res 1989;49:2639-2644.
10. Wessels BW, Rogus RD. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. Med Phys 1984;11:638-645.
11. Sundberg MW, Meares CF, Goodwin DA, Diamante CT. Chelating agents for the binding of metal ions to macromolecules. Nature 1974;250:587-588.
12. Meares CF, Wensel TG. Metal chelates as probes of biological systems. Acc Chem Res 1984;17:202-209.
13. Brinkley M. A brief survey of methods for preparing protein conjugates with dyes, haptens and cross-linking agents. Chemistry 1992;3:2-13.
14. Klein JL, Nguyen TH, Laroque P, et al. Yttrium-90 and iodine-131 radioimmunoglobulin therapy of an experimental human hepatoma. Cancer Res 1989;49:6383-6389.
15. Renn O, Meares CF. Large-scale synthesis of the bifunctional chelating agent 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N′,N′,N‴- tetraacetic acid, and the determination of its enantiomeric purity by chiral chromatography. Bioconj Chem 1992;3:563-569.
16. Moi MK, Meares CF, DeNardo SJ. The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴- tetraacetic acid and the study of its yttrium (III) complex. J Am Chem Soc 1988;110:6266-6267.
17. Goodwin DA, Meares CF, McCall MJ, et al. Chelate conjugates of monoclonal antibodies for imaging lymphoid structures in the mouse. J Nucl Med 1985;26:493-502.
18. Goodwin DA. Pharmacokinetics and antibodies. J Nucl Med 1987;28:1358-1362.
19. Begent RHJ, Green AJ, Bagshawe KD, et al. Liposomally entrapped second antibody improves tumor imaging with radiolabeled (first) antitumor antibody. Lancet 1982;ii: 739-742.
20. Rowlinson G, Snook D, Busza A, Epenetos AA. Antibody guided localization of intraperitoneal tumors following intraperitoneal or intravenous antibody administration. Cancer Res 1987;47:6528-6531.
21. 111 In-chelate conjugated anti-idiotype monoclonal antibody for radioimmunodetection of lymphoma in mice. Eur J Nucl Med 1986;12:455-460.
22. Shi XB, Gumerlock PH, Wellman AA, et al. Rapid PCR construction of a gene containing Lym-1 antibody variable regions. PCR Methods Appl 1993;3:46-53.
23. Goodwin DA, Meares CF, McCall MJ, McTigue M, Chaovapong W. Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J Nucl Med 1988;29:226-234.
24. Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med 1987;28:1249-1302.
25. Le Doussal J-M, Martin M, Gautherot E, Delaage M, Barbet J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med 1989;30:1358-1366.
26. Paganelli GM, Fazio, F. Monoclonal antibody pretargeting techniques for tumor localization: the avidin/biotin system. Nucl Med Commun 1991;12:211-234.
27. Goodwin DA, Meares CF. Pretargeting. General principles. Cancer 1997;80:2675-2680.
28. Yuan F, Baxter LT, Jain RK. Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies. Cancer Res 1991;51:3119-3130.
29. Wilchek M, Bayer EA. The avidin/biotin complex in immunology, Immunol Today 1984;5:39-43.
30. Wilchek M, Bayer EA. The avidin/biotin complex in bioanalytical applications. Anal Biochem 1988;171:1-32.
31. Green NM. Avidin. Adv Protein Chem 1975;29:85-133.
32. 14C]biotin for kinetic studies and for assay. Biochemistry 1963;89:585-591.
33. Paganelli G, Riva P, Deleide G, et al. In vivo labeling of biotinylated antibodies by radioactive avidin: a strategy to increase tumor localization. Int J Cancer 1988;2:121-125.
34. Paganelli G, Chinol M, C G, et al. Therapy trials in cancer patients using an improved 3-step pretargeting approach. In: Bergman H, Kaa SH, ed. Radioactive isotopes in clinical medicine and research. Basel: Birkhäuser Verlag; 1996:513-517.
35. Renn O, Goodwin DA, Studer M, Moran JK, Jacques V, Meares CF. New approaches to delivering metal-labeled antibodies to tumors: synthesis and characterization of new biotinyl chelate conjugates for pre-targeted diagnosis and therapy. J Controlled Release 1996;39:239-249.
36. Bos ES, Kuijpers WHA, Meesters-Winters M, et al. In vitro evaluation of DNA-DNA hybridization as a two-step approach in radioimmunotherapy of cancer. Cancer Res 1994;54:3479-3486.
37. Senter PD. Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy. FASEB J 1990;4:188-193.
38. Goodwin DA, Meares CF, Watanabe N, et al. Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and Y-88-JANUS-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclodecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for Y-90 radioimmunotherapy. Cancer Res 1994;54:5937-5946.
39. Paganelli G, Grana C, Chinol M, et al. Antibody guided three-step radiotherapy with 90-Y-biotin in glioma patients. In: Rowlinson-Busza DG, ed. The 14h international conference on advances in the application of monoclonal antibodies in coincidental oncology. Santorini, Greece: Thira; 1997:47.
40. Schechter B, Silberman R, Arnon R, Wilchek M. Tissue distribution of avidin and streptavidin injected to mice. Effect of avidin carbohydrate, streptavidin truncation and exogenous biotin. Eur J Biochem 1990;189:327-331.
41. Rosebrough SF. Plasma stability and pharmacokinetics of radiolabeled deferoxaminebiotin derivatives. J Pharmacol Exp Ther 1993;265:408-415.
42. Paganelli G, Magnani P, Zito F, et al. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res 1991;51:5960-5966.
43. 90Y delivery to mouse tumor xenografts [Abstract]. Tumor Targeting 1996;2:156.